hpjet
Member
FDA will not require clinical trial data in approving new redesigned Covid boosters against BA.4 and BA.5. Instead they will rely on the merits of the clinical trial data on efficacy and safety of the vaccine formulated for the original BA.1 variant. https://www.reuters.com/legal/gover...thorize-redesigned-covid-boosters-2022-06-30/